Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 abiraterone acetate plus prednisolone in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer
2008-008004-41Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing abiraterone acetate + prednisolone with placebo + prednisolone (2 arms). Started May 2009; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2008-008004-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008004-41.